Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes

Nie,Zhigang; Peng,Hao

doi:10.3892/ol.2018.9453

Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes

Authors:
- Zhigang Nie
- Hao Peng
View Affiliations

Affiliations: Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: September 18, 2018 https://doi.org/10.3892/ol.2018.9453
Pages: 6502-6514
Copyright: © Nie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Only few systematic and comprehensive studies have focused on osteosarcoma in children and adolescents. In the present study, 3,085 patients with osteosarcoma were identified in the Surveillance, Epidemiology and End Results Program database. The patients were <25 years of age and diagnosed between 1973 to 2012. A retrospective study was performed to investigate the factors associated with tumor incidence, metastasis, treatment and survival. The results indicated that the incidence of osteosarcoma was higher in male patients compared with female patients. In addition, the incidence rate of osteosarcoma was higher among male and female patients between the ages of 10 and 19. Osteosarcoma located in the chest and pelvic bones was associated with metastatic disease; however, metastasis in two histological types, parosteal and periosteal, was infrequent. Survival analysis revealed the following were associated with poor outcomes: Sex, patients diagnosed between 1973 and 1982, distant metastasis, treatment without surgery or with radiation, a tumor with a poorly differentiated or undifferentiated grade, tumor size ≥100 mm, and a tumor in the pelvic bones. Patient's whose histologic type was parosteal osteosarcoma and whose tumor was located in one of the limbs, or who underwent local or radical excision, exhibited a good survival outcome. Survival outcomes were ranked according to the type of surgery, from best to worst, as follows: Local excision, radical excision, amputation and no surgery. In summary, the incidence of osteosarcoma is higher in male patients compared with female patients. Furthermore, individuals between the ages of 10 and 19 have a higher risk of osteosarcoma. Osteosarcoma located in the chest and pelvic bones has a high risk of metastasis. Limb‑salvage surgery may be the optimal treatment approach for non‑metastatic osteosarcoma.

View Figures

View References

1	Damron TA, Ward WG and Stewart A: Osteosarcoma, chondrosarcoma, and ewing's sarcoma: National cancer data base report. Clin Orthop Relat Res. 459:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
2	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
3	Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS and Grotmol T: Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976–2005). Cancer Epidemiol Biomarkers Prev. 20:1770–1777. 2011. View Article : Google Scholar : PubMed/NCBI
4	Duong LM and Richardson LC: Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999–2008. J Registry Manag. 40:59–64. 2013.PubMed/NCBI
5	Tsuda Y, Ogura K, Shinoda Y, Kobayashi H, Tanaka S and Kawai A: The outcomes and prognostic factors in patients with osteosarcoma according to age: A Japanese nationwide study with focusing on the age differences. BMC Cancer. 18:6142018. View Article : Google Scholar : PubMed/NCBI
6	Wang W, Yang J, Wang Y, Wang D, Han G, Jia J, Xu M and Bi W: Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution. Pathol Res Pract. 213:119–125. 2017. View Article : Google Scholar : PubMed/NCBI
7	Schrager J, Patzer RE, Mink PJ, Ward KC and Goodman M: Survival outcomes of pediatric osteosarcoma and Ewing's sarcoma: A comparison of surgery type within the SEER database, 1988–2007. J Registry Manag. 38:153–161. 2011.PubMed/NCBI
8	Perkins SM, Shinohara ET, DeWees T and Frangoul H: Outcome for children with metastatic solid tumors over the last four decades. PLoS One. 9:e1003962014. View Article : Google Scholar : PubMed/NCBI
9	Gatta G, Capocaccia R, Coleman MP, Ries LA and Berrino F: Childhood cancer survival in europe and the united states. Cancer. 95:1767–1772. 2002. View Article : Google Scholar : PubMed/NCBI
10	Novakovic B: U.S. childhood cancer survival, 1973–1987. Med Pediatr Oncol. 23:480–486. 1994. View Article : Google Scholar : PubMed/NCBI
11	Duchman KR, Gao Y and Miller BJ: Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 39:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
12	Foster L, Dall GF, Reid R, Wallace WH and Porter DE: Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br. 89:1234–1238. 2007. View Article : Google Scholar : PubMed/NCBI
13	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
14	Duffaud F, Digue L, Mercier C, Dales JP, Baciuchka-Palmaro M, Volot F, Thomas P and Favre R: Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer. 39:2050–2057. 2003. View Article : Google Scholar : PubMed/NCBI
15	Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Miyake K, Kiyuna T, Miyake M, Murakami T, Chmielowski B, et al: Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as-positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. Oncotarget. 9:915–923. 2018. View Article : Google Scholar : PubMed/NCBI
16	Murakami T, Igarashi K, Kawaguchi K, Kiyuna T, Zhang Y, Zhao M, Hiroshima Y, Nelson SD, Dry SM, Li Y, et al: Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget. 8:8035–8042. 2017. View Article : Google Scholar : PubMed/NCBI
17	Igarashi K, Kawaguchi K, Murakami T, Kiyuna T, Miyake K, Nelson SD, Dry SM, Li Y, Yanagawa J, Russell TA, et al: Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Cell Cycle. 16:1164–1170. 2017. View Article : Google Scholar : PubMed/NCBI
18	Igarashi K, Murakami T, Kawaguchi K, Kiyuna T, Miyake K, Zhang Y, Nelson SD, Dry SM, Li Y, Yanagawa J, et al: A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: Implications for precision oncology. Oncotarget. 8:62111–62119. 2017. View Article : Google Scholar : PubMed/NCBI
19	Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, et al: Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. Oncotarget. 9:7774–7781. 2017.PubMed/NCBI
20	Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patino-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schuz J, Craft AW and Savage SA: Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control. 22:899–908. 2011. View Article : Google Scholar : PubMed/NCBI
21	Arora RS, Alston RD, Eden TO, Geraci M and Birch JM: The contrasting age-incidence patterns of bone tumours in teenagers and young adults: Implications for aetiology. Int J Cancer. 131:1678–1685. 2012. View Article : Google Scholar : PubMed/NCBI
22	Greil H and Kahl H: Assessment of developmental age: Cross-sectional analysis of secondary sexual characteristics. Anthropol Anz. 63:63–75. 2005.PubMed/NCBI
23	Longhi A, Pasini A, Cicognani A, Baronio F, Pellacani A, Baldini N and Bacci G: Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol. 27:314–318. 2005. View Article : Google Scholar : PubMed/NCBI
24	Gelberg KH, Fitzgerald EF, Hwang S and Dubrow R: Growth and development and other risk factors for osteosarcoma in children and young adults. Int J Epidemiol. 26:272–278. 1997. View Article : Google Scholar : PubMed/NCBI
25	Endicott AA, Morimoto LM, Kline CN, Wiemels JL, Metayer C and Walsh KM: Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. Pediatr Blood Cancer. 64:2017. View Article : Google Scholar : PubMed/NCBI
26	Homa DM, Sowers MR and Schwartz AG: Incidence and survival rates of children and young adults with osteogenic sarcoma. Cancer. 67:2219–2223. 1991. View Article : Google Scholar : PubMed/NCBI
27	Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, Figueiredo MT, Marques E, De Bellis N and Consentino E: Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer. 68:733–737. 1991. View Article : Google Scholar : PubMed/NCBI
28	Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 39:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
29	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
30	Saeter G, Elomaa I, Wahlqvist Y, Alvegard TA, Wiebe T, Monge O, Forrestier E and Solheim OP: Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl. 273:156–160. 1997. View Article : Google Scholar : PubMed/NCBI
31	Guillon MA, Mary PM, Brugiere L, Marec-Berard P, Pacquement HD, Schmitt C, Guinebretiere JM and Tabone MD: Clinical characteristics and prognosis of osteosarcoma in young children: A retrospective series of 15 cases. BMC Cancer. 11:4072011. View Article : Google Scholar : PubMed/NCBI
32	Worch J, Matthay KK, Neuhaus J, Goldsby R and DuBois SG: Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer. 55:285–289. 2010. View Article : Google Scholar : PubMed/NCBI
33	Sugalski AJ, Jiwani A, Ketchum NS, Cornell J, Williams R, Heim-Hall J, Hung JY and Langevin AM: Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in south texas. J Pediatr Hematol Oncol. 36:e353–e358. 2014. View Article : Google Scholar : PubMed/NCBI
34	Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, Flucke U, Schreuder HW and te Loo DM: Age as prognostic factor in patients with osteosarcoma. Bone. 49:1173–1177. 2011. View Article : Google Scholar : PubMed/NCBI
35	Neel MD, Wilkins RM, Rao BN and Kelly CM: Early multicenter experience with a noninvasive expandable prosthesis. Clin Orthop Relat Res. 1–81. 2003.
36	Miller BJ, Cram P, Lynch CF and Buckwalter JA: Risk factors for metastatic disease at presentation with osteosarcoma: An analysis of the SEER database. J Bone Joint Surg Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
37	Jawad MU, Cheung MC, Clarke J, Koniaris LG and Scully SP: Osteosarcoma: Improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol. 137:597–607. 2011. View Article : Google Scholar : PubMed/NCBI
38	Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
39	Lee JA: Osteosarcoma in Korean children and adolescents. Korean J Pediatr. 58:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
40	Kantar M, Cetingul N, Azarsiz S, Kansoy S, Sabah D, Memis A, Basdemir G and Burak Z: Treatment results of osteosarcoma of the extremity in children and adolescents at ege university hospital. Pediatr Hematol Oncol. 19:475–482. 2002. View Article : Google Scholar : PubMed/NCBI
41	Nakajima H, Sim FH, Bond JR and Unni KK: Small cell osteosarcoma of bone. Review of 72 cases. Cancer. 79:2095–2106. 1997. View Article : Google Scholar : PubMed/NCBI
42	Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 1–291. 2004.PubMed/NCBI
43	Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G and Lari S: Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 97:3068–3075. 2003. View Article : Google Scholar : PubMed/NCBI
44	Janinis J, McTiernan A, Driver D, Mitchell C, Cassoni AM, Pringle J, Kilby A and Whelan JS: London Bone and Soft Tissue Tumour Service: A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. Ann Oncol. 13:1935–1944. 2002. View Article : Google Scholar : PubMed/NCBI
45	Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, Gronchi A, Parafioriti A, Gandola L, Collini P, Ferrari A, et al: Axial skeletal osteosarcoma: A 25-year monoinstitutional experience in children and adolescents. Med Oncol. 31:8752014. View Article : Google Scholar : PubMed/NCBI
46	Akyuz C, Ilhan I, Kutluk T and Buyukpamukcu M: Primary osteosarcoma presenting in axial bones in childhood. Turk J Pediatr. 37:375–381. 1995.PubMed/NCBI
47	Han G, Bi WZ, Xu M, Jia JP and Wang Y: Amputation versus limb-salvage surgery in patients with osteosarcoma: A meta-analysis. World J Surg. 40:2016–2027. 2016. View Article : Google Scholar : PubMed/NCBI
48	Li X, Zhang Y, Wan S, Li H, Li D, Xia J, Yuan Z, Ren M, Yu S, Li S, et al: A comparative study between limb-salvage and amputation for treating osteosarcoma. J Bone Oncol. 5:15–21. 2016. View Article : Google Scholar : PubMed/NCBI
49	Grimer RJ: Surgical options for children with osteosarcoma. Lancet Oncol. 6:85–92. 2005. View Article : Google Scholar : PubMed/NCBI
50	Wafa H and Grimer RJ: Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther. 6:239–248. 2006. View Article : Google Scholar : PubMed/NCBI
51	Postma A, Kingma A, De Ruiter JH, Koops Schraffordt H, Veth RP, Goeken LN and Kamps WA: Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremity. J Surg Oncol. 51:47–51. 1992. View Article : Google Scholar : PubMed/NCBI
52	Aksnes LH, Bauer HC, Jebsen NL, Folleras G, Allert C, Haugen GS and Hall KS: Limb-sparing surgery preserves more function than amputation: A Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 90:786–794. 2008. View Article : Google Scholar : PubMed/NCBI
53	Picci P, Sangiorgi L, Bahamonde L, Aluigi P, Bibiloni J, Zavatta M, Mercuri M, Briccoli A and Campanacci M: Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol. 8:899–903. 1997. View Article : Google Scholar : PubMed/NCBI